



**Final Appraisal Recommendation**  
Advice No: 0521 –March 2021

**Idebenone (Raxone®) 150 mg film-coated tablets**

**Submission by Chiesi Limited**

**Recommendation of AWMSG**

**Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.**

**Additional note(s):**

- AWMSG considered idebenone (Raxone®) as an ultra-orphan medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 807), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available), the lay member perspective and the summary of the Clinical and Patient Involvement Group (CAPIG) meeting.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0521:  
Idebenone (Raxone®) 150 mg film-coated tablets March 2021



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>